In general, studies of SNHG15 modulating NF-κB and NF-κB-mediated EMT in particular, have opened up avenues for the potential targeted oncogenic NF-κB signaling therapy in metastatic cancers. Here, NFKB1 is linked to metastatic malignant neoplasm.